VERVE THERAPEUTICS INC. - COMMON STOCK

Verve Therapeutics Announces Pipeline Progress and Expansion and Reports First Quarter 2023 Financial Results

15 May 2023 05:30:00 By Nasdaq GlobeNewswire

Verve Therapeutics to Participate in the RBC Capital Markets 2023 Global Healthcare Conference

09 May 2023 05:30:00 By Nasdaq GlobeNewswire

Verve Therapeutics to Participate in the Guggenheim 2023 Genomic Medicines and Rare Disease Day

27 Mar 2023 05:30:00 By Nasdaq GlobeNewswire

Verve Therapeutics Reports New Preclinical Data Demonstrating Potent and Durable Editing of ANGPTL3 Gene with VERVE-201 in Wild-type and LDLR-deficient Non-Human Primates

03 Mar 2023 05:30:00 By Nasdaq GlobeNewswire

Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2022 Financial Results

02 Mar 2023 05:30:00 By Nasdaq GlobeNewswire

Verve Therapeutics Announces VERVE-101 Awarded Innovation Passport by the UK MHRA for the Treatment of Heterozygous Familial Hypercholesterolemia

14 Feb 2023 05:30:00 By Nasdaq GlobeNewswire

Verve Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

03 Jan 2023 15:05:00 By Nasdaq GlobeNewswire

Verve Therapeutics to Participate in Upcoming Investor Conferences

11 Nov 2022 05:30:00 By Nasdaq GlobeNewswire

Verve Therapeutics Provides Regulatory Update on VERVE-101 Investigational New Drug Application and Reports Third Quarter 2022 Financial Results

07 Nov 2022 05:30:00 By Nasdaq GlobeNewswire

Verve Therapeutics Announces Publication of VERVE-101 Preclinical Data in Circulation and Presentations at the American Heart Association Annual Meeting

31 Oct 2022 06:00:00 By Nasdaq GlobeNewswire

Verve Therapeutics to Participate in Upcoming Investor Conferences

22 Sep 2022 05:30:00 By Nasdaq GlobeNewswire

Verve Therapeutics Announces Clearance of Clinical Trial Authorisation Application by the United Kingdom Medicines and Healthcare Products Regulatory Agency for VERVE-101 in Patients with Heterozygous Familial Hypercholesterolemia

21 Sep 2022 05:30:00 By Nasdaq GlobeNewswire

Verve Therapeutics Highlights Preclinical Data Supporting Nomination of VERVE-201 ANGPTL3 Product Candidate at the European Society of Cardiology 2022 Congress

22 Aug 2022 05:30:00 By Nasdaq GlobeNewswire

Verve Therapeutics Provides Corporate Updates and Reports Second Quarter 2022 Financial Results

09 Aug 2022 05:30:00 By Nasdaq GlobeNewswire

Verve Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

25 Jul 2022 15:01:00 By Nasdaq GlobeNewswire

Verve Therapeutics Announces Pricing of Upsized Public Offering of Common Stock

21 Jul 2022 05:30:00 By Nasdaq GlobeNewswire

Verve Therapeutics Announces Proposed Public Offering of Common Stock

20 Jul 2022 15:02:00 By Nasdaq GlobeNewswire

Vertex and Verve Therapeutics Establish Collaboration to Discover and Develop an In Vivo Gene Editing Program for Liver Disease

20 Jul 2022 15:01:00 By Nasdaq GlobeNewswire

Verve Therapeutics Doses First Human with an Investigational In Vivo Base Editing Medicine, VERVE-101, as a Potential Treatment for Heterozygous Familial Hypercholesterolemia

12 Jul 2022 05:30:00 By Nasdaq GlobeNewswire

Verve Therapeutics Appoints Experienced Biotechnology Executive, Alexander G. “Bo” Cumbo, to its Board of Directors

13 Jun 2022 05:30:00 By Nasdaq GlobeNewswire